CD8A and neoplasm: This antitumor immune function of CD96 may be derived from the interaction of CD155/CD112 on tumor cells or antigen-presenting cells in the TME with TIGIT/CD96 on CD8 T cells or NK cells, resulting in the inhibition of antitumor NK cells and T cell functions (Dougall et al., 2017).